home / stock / snse / snse news

SNSE News and Press, Sensei Biotherapeutics Inc.

Stock Information
Company Name: Sensei Biotherapeutics Inc.
Stock Symbol: SNSE
Market: NASDAQ
Menu
SNSE SNSE Quote SNSE Short SNSE News SNSE Articles SNSE Message Board
Get SNSE Alerts

News, Short Squeeze, Breakout and More Instantly...
SNSE - US Companies Moving the Markets, Evening edition
Fri, May 24, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 428.5% to $0.983 on volume of 924,758,481 shares Greenwave Technology Solutions Inc. (GWAV) fell 4.2% to $0.0849 on volume of 393,457,542 shares Netcapital Inc. (NCPL) rose 10.1% to $0.1925 on volum...
SNSE - Sensei stock plunges 46% in wake of Phase 1 data

2024-05-24 13:42:55 ET More on Sensei Biotherapeutics Seeking Alpha’s Quant Rating on Sensei Biotherapeutics Historical earnings data for Sensei Biotherapeutics Financial information for Sensei Biotherapeutics Read the full article on Seeking Alpha ...

SNSE - LIDR, HOOK and BCAB among mid-day movers

2024-05-24 12:58:09 ET More on BioAtla, HOOKIPA Pharma, etc. BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript BioAtla: A Buried ADC Concern Gets Some New Life In 2024 AEye Q1 2024 Earnings Preview ...

SNSE - US Companies Moving the Markets, Morning edition
Fri, May 24, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
SNSE - AIMD, BCG and RENB among pre-market losers

2024-05-24 08:16:00 ET More on pre-market losers & stocks. RenovaroCube to acquire 100% ownership of Cyclomics Financial information for Ainos Financial information for Binah Capital Group, Inc. Financial information for Renovaro Inc. Compare metr...

SNSE - Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEW...

SNSE - CureVac, Oragenics, IGM Biosciences among healthcare movers

2024-05-22 10:00:31 ET More on etc. Replimune: Continuing To Justify The Bear Thesis (For Now) Gold At $3,000 Is The Wrong Way To Think About The Precious Metal Best Buy: Poised For Growth Amid E-Commerce Threat Nvidia’s upcoming earnings has investors...
SNSE - Overweight Recommendation Issued On SNSE By Stephens

2024-05-13 18:15:04 ET Stephens analyst issues OVERWEIGHT recommendation for SNSE on May 13, 2024 04:20PM ET. SNSE was trading at $1.57 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendati...

SNSE - SNSE Price Target Alert: $5.00. Issued by Stephens

2024-05-13 18:00:03 ET Sudan Loganathan from Stephens issued a price target of $5.00 for SNSE on 2024-05-13 16:20:00. The adjusted price target was set to $5.00. At the time of the announcement, SNSE was trading at $1.57. The overall price target consensus is at $6.00 wi...

SNSE - Sensei Biotherapeutics GAAP EPS of -$0.32

2024-05-09 11:09:34 ET More on Sensei Biotherapeutics Seeking Alpha’s Quant Rating on Sensei Biotherapeutics Historical earnings data for Sensei Biotherapeutics Financial information for Sensei Biotherapeutics Read the full article on Seeking Alpha ...
Next 10